32 reports

  • SOCIAL ANXIETY DISORDERS (SAD) THERAPEUTICS, G7 COUNTRIES, CLINICAL TRIALS BY PHASE, 2018*
  • SOCIAL ANXIETY DISORDERS (SAD) THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY REGION (%), 2018*

SOCIAL ANXIETY DISORDERS (SAD) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2018* CLINICAL TRIALS BY END POINT STATUS SOCIAL ANXIETY DISORDERS (SAD) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2018* SOCIAL ANXIETY

  • Anxiety Disorder
  • Neurology
  • Therapy
  • World
  • Product Initiative
  • Introduction
  • Executive Summary

Executive Summary THIS REPORT PROVIDES AN OVERVIEW OF THE PIPELINE LANDSCAPE FOR DEPRESSION AND ANXIETY DISORDERS.

  • Anxiety Disorder
  • Depression
  • Company
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.

General Anxiety Disorder Ongoing Global Clinical Trials Analysis and Outlook ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Key Findings, 2018 ##. ## Snapshot ##. ## Overview of General Anxiety Disorder Trials ## Clinical Trials Trends to 2022 ##. ##

  • Anxiety Disorder
  • Clinical Trial
  • Drug Development
  • Mental Health
  • Pathology

Social Anxiety Disorders (SAD) Ongoing Global Clinical Trials Analysis and Outlook ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Key Findings, 2018 ##. ## Snapshot ##. ## Overview of Social Anxiety Disorders (SAD) Trials ## Clinical Trials Trends

  • Anxiety Disorder
  • Clinical Trial
  • Drug Development
  • Mental Health

Global Anxiety Disorder Epidemiology and Patient Flow Analysis - 2017 ##.

  • Anxiety Disorder
  • France
  • United States
  • World
  • Forecast

2019 Social Anxiety Disorders (SAD) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 ##.

  • Anxiety Disorder
  • Clinical Trial
  • Drug Development
  • Mental Health

2019 Social Anxiety Disorders (SAD) Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets ##.

  • Anxiety Disorder
  • Clinical Trial
  • Drug Development
  • Mental Health
  • APAC

Europe Anxiety Disorder Epidemiology and Patient Flow Analysis - 2017 ##.

  • Anxiety Disorder
  • Europe
  • France
  • Germany
  • Forecast

Anxiety disorders and depression treatment market, 2014 - 2025 (USD Million) ##. ##. ## Canada ##. ##. ##. ## Canada anxiety disorders and depression treatment market, 2014 - 2025 (USD Million) ##. ## Europe ##. ##. ## Europe anxiety disorders and depression treatme

  • Antidepressant
  • Anxiety Disorder
  • Therapy
  • United States
  • Market Size
  • Anxiety Disorders - Discontinued Products
  • Anxiety Disorders Overview

Signal Pharma NA NA SMALL MOLECULE TO ANTAGONIZE CRF-## RECEPTOR FOR ANXIETY DISORDERS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Small Molecule to Antagonize CRF-## Receptor for

  • Anxiety Disorder
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative
  • Anxiety Disorders - Discontinued Products
  • Anxiety Disorders - Dormant Projects

ANXIETY DISORDERS - PIPELINE BY F.

  • Anxiety Disorder
  • Pharmaceutical
  • Research And Development
  • United States
  • Company Operations
  • PIPELINE BY BIONOMICS LTD, H1 2019
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2019

The drug candidate is in Phase II stage of development for post traumatic stress disorder and agitation (anxiety disorder).

  • Anxiety Disorder
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Bionomics
  • Clinical Trial profile. 55 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Anxiety Disorders, Depression, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorders, Post- Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorders (SAD), S

  • Anxiety Disorder
  • Clinical Trial
  • World
  • Product Initiative
  • Pfizer Inc.
  • Target
  • Target

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Anxiety Disorder
  • Mental Health
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • PIPELINE BY BIONOMICS LTD, H2 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018

Every year in Australia, approximately ## per cent of the population (## in ##) experiences an anxiety disorder and ##. ## percent experiences GAD.

  • Anxiety Disorder
  • United States
  • World
  • Product Initiative
  • Bionomics
  • 2.1 RELATED REPORTS
  • 3.3 GLOBAL AND HISTORICAL TRENDS

PTSD sufferers typically exhibit comorbid disorders including major depression, anxiety disorders, and substance use disorders as well as a higher rate of suicide attempts.

  • Anxiety Disorder
  • Japan
  • United States
  • World
  • Forecast
  • Target
  • Target

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Anxiety Disorder
  • Clinical Trial
  • Pharmaceutical
  • World
  • Product Initiative
  • Key clinical trial approval
  • 11.1 Factors impacting market growth

Anxiety disorders is one of the most frequently occurring mental disorders, affecting individuals of all age groups.

  • Anxiety Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS
  • Clinical Trial profile. 2 Trial Title

GDCT ID is the unique ID of GlobalData' s Pharma Intelligence Center clinical trial database Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Sponsor(s) Collaborator(s) Estimated Start Da

  • Anxiety Disorder
  • Hormone
  • World
  • Product Initiative
  • Pfizer Inc.
  • Target
  • Clinical Trial profile. 60 Trial Title

PANIC DISORDERS THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* PANIC DISORDERS THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* PANIC DISORDERS THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* Company Name Phase IV

  • Anxiety Disorder
  • Pharmaceutical
  • World
  • Product Initiative
  • Pfizer Inc.

Pharma GmbH, Austria) with the Reference Product Cymbalta (Duloxetine) ## mg Gastro-Resistant Capsules (Eli Lilly Nederland BV, NL) in Healthy Male Subjects under Fed Conditions GDCT## GDC##, Central Nervous System Diabetic Neuropathic Pain, Generalized Anxiety Disorder

  • Anxiety Disorder
  • Clinical Trial
  • Depression
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 80 Trial Title

Anxiety Disorders, Depression, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorders, Post- Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorders (SAD), S

  • Anxiety Disorder
  • Therapy
  • World
  • Product Initiative
  • Pfizer Inc.
  • Target
  • Target

The program is supported by earlier clinical studies examining the biological effects of BNC## on the brain, on anxiety-induced behaviour in patients with Generalized Anxiety Disorder (GAD) and the ability to suppress panic attacks, " said Dr.

  • Anxiety Disorder
  • Clinical Trial
  • World
  • Product Initiative
  • Tonix Pharmaceuticals Holding Corp.

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Chronic Pain
  • Clinical Trial
  • Pharmaceutical
  • Eli Lilly & Co.
  • PTSD THERAPEUTICS MARKET IN AMERICAS
  • MARKET DEFINITION

SSRIs are generally indicated for depression, panic disorder, social anxiety disorder/ social phobia, bulimia nervosa, obsessive-compulsive disorder (OCD), PTSD, generalized anxiety disorder, and premenstrual syndrome.

  • Anxiety Disorder
  • Eli Lilly & Co Ltd
  • GlaxoSmithKline plc
  • Lundbeck Inc.
  • Pfizer Inc.
  • Global Anxiety Disorders Market
  • 06. Types of Anxiety Disorders

Types of Anxiety Disorders Anxiety disorders can be classified into the following.

  • Anxiety Disorder
  • World
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Clinical Trial profile. 13 Trial Title
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Hormone
  • World
  • Product Initiative
  • Torrent

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Chronic Pain
  • Clinical Trial
  • Pharmaceutical
  • Eli Lilly & Co.
  • HM-107 - DRUG PROFILE
  • POST-TRAUMATIC STRESS DISORDER (PTSD) - DORMANT PROJECTS, H1 2019 (CONTD..1), H1 2019

IT IS IN PHASE I STAGE OF DEVELOPMENT FOR ANXIETY DISORDERS.

  • Anxiety Disorder
  • Therapy
  • United States
  • Product Initiative
  • Tonix Pharmaceuticals Holding Corp.
  • R&D Progress
  • POST-TRAUMATIC STRESS DISORDER (PTSD) - DORMANT PROJECTS, H2 2018 (CONTD..1), H2 2018

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR GENERALIZED ANXIETY AND POST-TRAUMATIC STRESS DISORDER.

  • Anxiety Disorder
  • Pharmaceutical
  • Therapy
  • Product Initiative
  • Tonix Pharmaceuticals Holding Corp.